There is no information available regarding Uzedy survey results in the provided text.
What is Uzedy?
Uzedy, also known as a long-acting injectable form of risperidone, is a medication prescribed for the treatment of schizophrenia and schizoaffective disorder [1]. It is administered as an intramuscular injection and is designed to release the active ingredient over an extended period, potentially improving treatment adherence for patients [1][2].
How does Uzedy work?
Uzedy is a long-acting injectable (LAI) formulation of risperidone [1]. Risperidone is an atypical antipsychotic that works by affecting certain chemical messengers in the brain, specifically dopamine and serotonin [1][3]. By modulating these neurotransmitters, it helps to manage symptoms associated with schizophrenia and schizoaffective disorder, such as hallucinations, delusions, and disorganized thinking [1]. The long-acting formulation ensures a steady release of the medication, reducing the need for daily oral dosing and potentially leading to more consistent therapeutic levels [2].
When did Uzedy get approved?
Uzedy was approved by the U.S. Food and Drug Administration (FDA) in September 2023 [1]. This approval allows for its use in the treatment of schizophrenia in adults [1].
Who makes Uzedy?
Uzedy is manufactured by Viatris Inc. [1].
How is Uzedy administered?
Uzedy is given as an intramuscular injection [1]. It is available in two dosage strengths: 273 mg and 410 mg [1]. The injection is typically administered by a healthcare professional [2].
What are the potential benefits of Uzedy?
As a long-acting injectable, Uzedy offers the potential for improved treatment adherence compared to daily oral medications [2]. This can lead to more consistent control of schizophrenia symptoms and reduce the risk of relapse [1][2]. The extended-release formulation aims to provide stable therapeutic levels of risperidone in the body over a prolonged period [2].